The new drug approval process involves several phases of laboratory and clinical testing that can take over a decade and cost hundreds of millions of dollars. Only about 1 in 1000 compounds that enter pre-clinical testing are approved for human testing. After pre-clinical animal testing, companies submit an Investigational New Drug (IND) application to the FDA to request permission for human clinical trials. If approved, the drug then enters three phases of clinical trials involving several hundred to thousands of human subjects to evaluate safety, efficacy, and proper dosing. If phase 3 trials are successful, companies submit a New Drug Application (NDA) to the FDA for review and potential approval allowing marketing and post-market safety surveillance.
This Presentation contains an introduction to clinical research.
* Basic definition of Clinical Research.
* Steps involved in clinical Research.
* Phases in Clinical Research.
* Types of clinical Trials.
Clinical Trials: Types and Design
Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional
Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management.
In these slides you can get the information of clinical trials which have four phase I,II,III, IV. before clinical trials, Pre-clinical studies should be completed.
This Presentation contains an introduction to clinical research.
* Basic definition of Clinical Research.
* Steps involved in clinical Research.
* Phases in Clinical Research.
* Types of clinical Trials.
Clinical Trials: Types and Design
Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional
Clinical Trial Study Team Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management.
In these slides you can get the information of clinical trials which have four phase I,II,III, IV. before clinical trials, Pre-clinical studies should be completed.
Amendments in Schedule Y in 2013,2014 inserted three new rules, new appendix XII: compensation in case of injury or death during clinical trial, amendments in ICD and appendix V inform consent form format.
Turacoz Healthcare Solutions provides clinical research and regulatory writing services for pharmaceutical companies. We tell you about the different components of a clinical study protocol, the document which is prepared before beginning of any clinical trial. To know more info, visit- goo.gl/C1ec0L or write to us at hello@turacoz.in and call us 011-40584280.
Regulations for drug approval in USA, E.U & India
Pharmaceutical industry is the most regulated of all the industries. Regulations are put in order to develop the most efficient and safe pharmaceutical products. It takes more than 8 to 15 years to develop a new drug product & costs more than $ 800 million.
CFTCC
2015 Learning about the IND/IDE Process and Reimbursements for New Drugs and Devices
Erika Segear Johnson, PhD, RAC
Regulatory Affairs Scientist
Duke Translational Medicine Institute
Introduces the basics of filing an Investigational Device Exeption (IDE) Application with the FDA
Amendments in Schedule Y in 2013,2014 inserted three new rules, new appendix XII: compensation in case of injury or death during clinical trial, amendments in ICD and appendix V inform consent form format.
Turacoz Healthcare Solutions provides clinical research and regulatory writing services for pharmaceutical companies. We tell you about the different components of a clinical study protocol, the document which is prepared before beginning of any clinical trial. To know more info, visit- goo.gl/C1ec0L or write to us at hello@turacoz.in and call us 011-40584280.
Regulations for drug approval in USA, E.U & India
Pharmaceutical industry is the most regulated of all the industries. Regulations are put in order to develop the most efficient and safe pharmaceutical products. It takes more than 8 to 15 years to develop a new drug product & costs more than $ 800 million.
CFTCC
2015 Learning about the IND/IDE Process and Reimbursements for New Drugs and Devices
Erika Segear Johnson, PhD, RAC
Regulatory Affairs Scientist
Duke Translational Medicine Institute
Introduces the basics of filing an Investigational Device Exeption (IDE) Application with the FDA
New Drug Opportunity Assessments Strat Planning For Future SuccessPharmacision LLC
Pharmaceutical Business Development, Marketing and Strategic Planning Groups need an early read on opportunities, but oftentimes don’t have time or budget for extensive market research.
Pharmacision presents a step by step opportunity assessment and valuation process through a case study format.
Benefits of employing this process:
Quickly weed out projects with very low probability of commercial success,
Construct a framework for deeper dive assessments to validate and refine assumptions when greater market knowledge is needed before making go/no go decisions, Support clinical development and commercialization strategic planning, Reduce overall costs.
Роль діалогу-бізнес влада при підготовці стратегічних документівUSAID LEV
Презентація Ігоря Бураковського на тематичній секції «Стратегічне планування розвитку МСП як елемент регіонального (місцевого) розвитку» в рамках Національної конференції «Аутсорсінг для місцевого економічного розвитку». 27.02.2017.
How to access and process FDA drug approval packages for use in researchErick Turner
FDA reviews on new drugs can be used to learn the results of unpublished studies. Unfortunately, the FDA website (Drugs@FDA) is not user-friendly, nor are these review documents. These slides explain how to navigate Drugs@FDA, and they provide tips on how to make documents easier to use.
These slides are based on, and expand upon, an article in the BMJ, available at http://www.bmj.com/content/347/bmj.f5992 .
Intervento di Roberto Piras,Barbieri & Associati Dottori Commercialisti di Bologna, in occasione dell'incontro "Marchi, brevetti e diritto d'autore" tenutosi lo scorso 13 marzo 2017 presso Unindustria Bologna.
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Typically, researchers discover new drugs through: New insights into a disease process that allow researchers to design a product to stop or reverse the effects of the disease. Many tests of molecular compounds to find possible beneficial effects against any of a large number of diseases.
In vitro antidiabetic activity like
Inhibition of Polysaccharide-Degrading Enzymes
Assay for α-Amylase
Assay for α-Glucosidase
Everted Sac Technique for Assaying α-Glucosidase
Assays forGLUT2TransportActivity
Perfusion of Jejunal Loops
Transport Activity of Brush Border Membrane Vesicles
Apical Expression of GLUT2
Evaluation of Glucose Absorption InVivo
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
3. New Drug Approval
• It takes 12-15 years and hundreds of million
dollars to get a new drug from the laboratory
onto the pharmacy shelf.
• Once a company develops a drug, it undergoes 3
½ of laboratory testing,
• Then an application is made to the U.S. Food and
Drug Administration (FDA) to begin testing the
drug in humans.
• Only 1 in 1000 of the compounds that enter
laboratory testing ever make it to human testing.
6. New Drug Approval Process
• : Abandoned Investigational
New Drug Applications
Case 1
•Advisory Committee
MaterialsCase 2
• FDA Advisory Committee
Member Conflict-of-Interest
Statements
Case 3
• Data about Disapproved
UsesCase 4
• Abandoned NDAs
Case 5
• Phase IV Protocols
Case 6
7. Pre-clinical testing
• When new drugs show
promise in lab testing, studies
are designed to evaluate
them further.
• These studies in animals are
referred to as “pre-clinical
studies.”
8. Pre-clinical testing
• Pre-clinical studies help establish boundaries
for safe use of the treatment if/when human
studies begin. (Animal Models :- to test drugs & side effects)
• Many new drugs and treatments are
abandoned at this step because they are
proven unsafe.
9. Clinical research and development
• The application to the FDA to request
permission to begin human testing is called an
Investigational New Drug application, or IND.
• The IND permits the use of an investigational
new drug for the sole purpose of conducting
clinical trials.
10. What is an IND ?
• IND is not a marketing application
• An exemption from the law which otherwise
requires that a drug (biologic, device) be
approved before it can be transported across
state lines
• The standard for approval is evidence of safety
and efficacy
• The IND exemption is granted for purposes of
clinical investigation (research)
11. Importance of the IND
• Affirms a body of knowledge about the
manufacturing, pharmacology, and toxicology
of the drug to support its use in human testing
• Requires that the clinical investigation(s) be
performed in accordance with Good Clinical
Practice (GCP)
• Provides an additional level of protection
through FDA oversight
12. Investigational New Drug (IND)
• There are three IND types:
Investigator IND
Emergency Use IND
Treatment IND
• There are two IND categories:
Commercial(Ultimate goal is to achieve
marketing approval for new product)
Research (non-commercial)
13. Investigator/Sponsor IND
• An Investigator IND is submitted by a physician who both
initiates and conducts an investigation, and under whose
immediate direction the investigational drug is administered
or dispensed .
• A Research IND is to be submitted for proposed study of
Unapproved drug
Approved product for
» New indication
» New patient population
• Motivation is not necessarily commercial in nature
14. Emergency Use IND
21 CFR 312.36
• It allows the FDA to authorize use of an experimental drug in
an emergency situation that does not allow time for
submission of an IND in accordance with 21CFR , Sec.
312.23 or Sec. 312.34
• It is also used for patients:
who do not meet the criteria of an existing study protocol
or if an approved study protocol does not exist.
Reserved for life-threatening situations
No standard acceptable treatment is available
15. Treatment IND
• Experimental drugs showing promise in clinical testing-safety
and efficacy.
• After completion of Phase I and II
Used for the treatment of serious or life threatening
conditions
• No alternate treatments available
• AIDS, Cancer
Made available while final clinical testing is completed and
reviewed by the FDA
Reduce reluctance of people to participate in expanded drug
16. Content and Format of the IND
21 CFR 312.23
• All available information impacting on SAFETY!
Animal studies
Pharmacology (ADME)
Toxicology (LD, Short, long, genotoxicity etc)
Previous clinical experience
Foreign and domestic sources
Scientific literature
17. Content and Format of the IND
21 CFR 312.23
• Test article information and proposed dosage
form
– Chemical structure
– Manufacturing and purification techniques
– Analytical testing methods
– Physical characteristics
– Stability
18. Content and Format of the IND
21 CFR 312.23
• Overall plan of study for next year (minimum)
• Proposed protocols with justification
• Patient Inclusion & Exclusion criteria
• Method of patient selection to prevent bias
• Identification & qualifications of investigators
& sub-investigators
• Assurances of investigator supervision
• Assurances sponsor monitor
• Identification of key responsible individuals
19. Content and Format of the IND
21 CFR 312.23
• Requirements
Form FDA 1571
Table of contents
Introductory statement
General investigational plan
Investigators brochure
Clinical protocols
Chemistry, manufacturing and control data
Pharmacology and toxicology data
Previous human experience
20. IND APPLICATION PROCESS
• IND contains:
– sufficient Chemistry, Manufacturing, and Control
– pre-clinical safety information and describes the proposed
human trial (Phase 1)
• Multi-disciplinary Review Team
• 30-Day Deadline for Decision
• Team Decision
– Yes? “Okay to Proceed” No? Clinical HOLD
• Communication to sponsor: What work must sponsor do
to get HOLD lifted?
21. 30-Day Safety
• Studies shall not be initiated until 30 days
after the date of receipt of the IND by the FDA
unless you receive earlier notification by the
FDA that studies may begin.
23. Phase 1 trials
• Drug is tested for its
interaction with the human
body.
• Trials are conducted to
determine the appropriate
dose range with regard to
safety and toxicity (NOT
efficacy).
• Trials are conducted on a
limited number (20-80) of
normal volunteers or
patients (such as patients
with cancer or AIDS).
24. Phase 1 trials
• Phase 1 trials often takes 9 to 18 months to
complete.
• Many drugs are abandoned in Phase 1 testing
because of problems with safety or toxicity.
25. Phase 2 trials
• Small-scale, well-controlled
trials evaluate the
preliminary safety & efficacy
in 100 to 300 patients with
the disease or condition to
be treated.
• May focus on dose-response,
dosing schedule or other
issues related to preliminary
safety and efficacy.
26. Phase 2 trials (IIa, IIb)
• Often takes 1 to 3 years to
complete.
• Additional animal testing
may be conducted at the
same time to obtain long-
term safety data.
• If studies show drug to be
safe and useful, testing may
proceed to Phase 3.
27. Phase 3 trials
The most extensive (and
expensive) testing of a
drug.
• These trials fully assess
safety, efficacy and drug
dosage in a large group
of patients with the
specific disease to be
tested.
28. Phase 3 trials
• Conducted on larger (100s
to 1000s) and more diverse
groups of patients with the
condition.
• Make comparisons between
the new treatment and a
placebo and/or the standard
treatment.
29. Phase 3 trials
• Trials help to better understand the drug’s
safety and uncover any adverse effects.
• Trials often take 2 to 5 years to complete.
32. Phase 4 trials (Post-marketing
surveillance)
• Companies continue clinical trials of a drug after
it has been approved for marketing.
• Phase 4 trials may be performed to learn more
about side effects and long-term risks and
benefits.
• Companies may also evaluate different
formulations of a drug (like sustained-release) or
test the drug for a different indication.
33. Phase 4 trials (Post-marketing
surveillance)
• The company must
continue to report
information about new
findings and problems
after drug approval.
• Health care providers can
report new findings to the
company or directly to the
FDA (consumers can
report information to the
FDA as well).